YU4792A - Postupak gajenja tumornih infiltirajućih limfocita - Google Patents

Postupak gajenja tumornih infiltirajućih limfocita

Info

Publication number
YU4792A
YU4792A YU4792A YU4792A YU4792A YU 4792 A YU4792 A YU 4792A YU 4792 A YU4792 A YU 4792A YU 4792 A YU4792 A YU 4792A YU 4792 A YU4792 A YU 4792A
Authority
YU
Yugoslavia
Prior art keywords
tumor
lymphocytes
infilting
cultivation
procedure
Prior art date
Application number
YU4792A
Other languages
English (en)
Inventor
Hsu Dihwei
W.K. Moore
H. Spits
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of YU4792A publication Critical patent/YU4792A/sh

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

POSTUPAK GAJENJA TUMORNIH INFILTIRAJUCIH LIMFOCITA, obezbedjen je postupak za korišćenje interleukina-10 u adoptivnoj imunoterapji raka. Populacija tumornih infiltrirajućih limfocita (TIL) i/ili limfokinski aktiviranih ćelija-ubica (LAK) ekspanduje se u kulturi u prisustvu interleukina-2 (IL-2) ili interleukina-10 (IL-10). Nakon davanja TIL i/ili LAK pacijentu, daju mu se i efikasne količine IL-2 i IL-10, kako bi se pojačala citotoksicnost TIL i/ili LAK prema ćelijama tumora i smanjila sporedna dejstva koja se javljaju zbog toga što IL-2 indukuje proizvodnju citokina u ćelijama pacijenta.
YU4792A 1991-01-16 1992-01-16 Postupak gajenja tumornih infiltirajućih limfocita YU4792A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60134291A 1991-01-16 1991-01-16

Publications (1)

Publication Number Publication Date
YU4792A true YU4792A (sh) 1994-09-09

Family

ID=47470692

Family Applications (1)

Application Number Title Priority Date Filing Date
YU4792A YU4792A (sh) 1991-01-16 1992-01-16 Postupak gajenja tumornih infiltirajućih limfocita

Country Status (1)

Country Link
YU (1) YU4792A (sh)

Similar Documents

Publication Publication Date Title
MY108267A (en) Use of interleukin-10 in adoptive immunotherapy of cancer
Sekine et al. A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients
DK0702560T3 (da) Immunforstærkning ved intermitterende interleukin-2 behandling
IL69731A0 (en) Homogeneous human interleukin 2,its preparation and pharmaceutical compositions containing it
DK66692D0 (da) En mammal cytokin, il-11
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
Fagan et al. Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells
Limb et al. Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2
YU4792A (sh) Postupak gajenja tumornih infiltirajućih limfocita
Toledano et al. Interferon-γ (IFN-γ) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity—IFN-γ-induced suppressive activity
Malkovska et al. Tumour immunotherapy
Grimm et al. The lymphokine-activated killer cell phenomenon: in vitro and in vivo studies
IZUMI et al. Enhanced induction of tumor-specific Lyt-1+ 2-T cell-mediated protective immunity by in vivo administration of interleukin 1
Durek et al. Effects of colony-stimulating factors on cellular cytotoxicity
Okamura et al. The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
Ikemoto et al. Combined effect of interleukin 2 and Bacillus Calmette-Guerin in the therapy of mice with transitional cell carcinoma
Booth et al. The Interleukins
Ben-Efraim Cancer immunotherapy: potential involvement of mediators
SHIMIZU et al. PROLIFERATION AND CYTO-TOXICITY OF LECTIN-INDUCED LYMPHOKINE-ACTIVATED KILLER (LILAK) CELLS
Shirasaka et al. Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor (s)
Kishimoto et al. Augmentation of Murine Lymphokine‐activated Killer Cell Induction by a Factor Produced by Nocardia rubra Cell Wall Skeleton‐stimulated T Cells
CAO THE CYTOTOXICITY TO AUTOLOGOUS TUMOR CELLS OF TUMOR-INFILTRATING LYMPHOCYTE (TIL) ACTIVATED BY IL-2 AND ITS COMPARISON WITH THE CYTOTOXICITY OF LAK CELLS
LLOYD CELL TO CELL TRANSFER OF INTERFERON-INDUCED ANTIPROLIFERATIVE ACTIVITY IN VITRO AND ANTIVIRAL ACTIVITY IN VIVO.
Suzuki et al. Mouse Recombinant Interferon-β Augments the Induction of Macrophage Cytolytic Activity by Interleukin-2In Vitro